Robert Goeltz II - Oct 28, 2025 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Signature
/s/ Carolyn Tang, Attorney-in-Fact
Stock symbol
RCUS
Transactions as of
Oct 28, 2025
Transactions value $
-$100,000
Form type
4
Date filed
10/29/2025, 08:54 AM
Previous filing
Jan 27, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Goeltz II Robert C. Chief Financial Officer C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD /s/ Carolyn Tang, Attorney-in-Fact 2025-10-29 0001653881

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Sale -$100K -5K -5.15% $20.00 92.1K Oct 28, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023.